<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03470441</url>
  </required_header>
  <id_info>
    <org_study_id>FDY-5301-201-US</org_study_id>
    <nct_id>NCT03470441</nct_id>
  </id_info>
  <brief_title>A Study of Acute Myocardial Infarction Using FDY-5301</brief_title>
  <official_title>A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faraday Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faraday Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of
      three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an experimental drug
      called FDY-5301 as a possible treatment to reduce the size of the injury to the heart caused
      by the heart attack. An experimental drug is one that is being tested and is not approved by
      the United States Food and Drug Administration (FDA).

      A heart attack occurs when a heart (coronary) artery supplying blood to the heart muscle
      becomes blocked and the heart muscle is injured. You will be having a cardiac catheterization
      procedure to clear the blockage in your coronary artery that caused your heart attack. This
      procedure works well but may not completely prevent some injury to the heart muscle which
      occurs when the blood supply is initially restored to the heart. This is known as
      &quot;reperfusion injury&quot;.

      FDY-5301 is a single intravenous injection. About 80 subjects are expected to participate in
      this study at about 20 research sites in the United States and Europe. Each subject's
      participation is expected to last about 6 months after receiving the study drug.

      Subjects who meet all inclusion criteria will be randomly assigned to one of 4 study groups.
      Three groups will receive FDY-5301 (low, intermediate, or high dose) and 1 group will receive
      a placebo.The study drug (FDY-5301 or placebo) will be given through a vein (intravenously)
      during the catheterization procedure. This is a double-blind study so neither the patient nor
      study personnel will know whether the dose is active drug or placebo until the end of the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Actual">January 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects who fulfill all study eligibility criteria will be randomized to receive one of the 4 treatments.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a double-blind study where all study staff and participants are blinded to whether the patient receives active drug or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Number and Incidence Rate of Several Arrhythmias</measure>
    <time_frame>Out to 14 days Post Percutaneous Coronary Intervention (PCI)</time_frame>
    <description>Combined number and incidence rate (defined as percentage of patients experiencing at least one of the arrhythmia types) of several arrhythmias including ventricular fibrillation, sustained ventricular tachycardia, non-sustained ventricular tachycardia and high degree AV block.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct Size</measure>
    <time_frame>72 hours and 3 months Post PCI</time_frame>
    <description>Infarct size assessed by cardiac magnetic resonance (CMR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment Resolution</measure>
    <time_frame>4 hours Post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T Level Measured in Serum Collected at Multiple Time Points</measure>
    <time_frame>Pre-study drug, 12, 24, and 48 hours post study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent arrhythmias</measure>
    <time_frame>30 days and 3 months Post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>72 hours and 3 months Post PCI</time_frame>
    <description>Measures of cardiac function assessed by CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Cardiac Injury, Inflammation, and Remodeling Measured in Serum Collected at Several Time Points</measure>
    <time_frame>Pre-study drug, 1, 4, 12, 24, and 48 hours and 3 months post study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Related Adverse Events Including Heart Failure and Mortality</measure>
    <time_frame>Out to 3 months Post PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>FDY-5301 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anticipated n=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDY-5301 Intermediate Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anticipated n=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDY-5301 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anticipated n=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Anticipated n=20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDY-5301</intervention_name>
    <description>FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.</description>
    <arm_group_label>FDY-5301 High Dose</arm_group_label>
    <arm_group_label>FDY-5301 Intermediate Dose</arm_group_label>
    <arm_group_label>FDY-5301 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-80 year old male subjects

          2. 18 to 80 year old female subjects who are not of child-bearing potential.

          3. Accepted for Primary PCI with diagnosis of first STEMI, based on clinical and ECG
             criteria (ST-elevation at the J-point in two contiguous leads with the cut-off points:
             ≥0.2 millivolt (mV) in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other
             leads), within 12 hours of symptom onset.

        Written informed consent prior to study participation (either by the subject or a legally
        authorized representative of the subject)

        Exclusion Criteria:

          1. Previous myocardial infarction

          2. Left bundle branch block (LBBB)

          3. Previous coronary artery bypass graft surgery (CABG)

          4. Major hemodynamic instability or uncontrolled ventricular arrhythmias

          5. Known contraindication to CMR

          6. Patients with known thyroid disease

          7. Subjects with past or current renal impairment requiring dialysis

          8. Pregnant or females of child bearing potential

          9. Body weight &gt; 120 kg or Body Mass Index (BMI) &gt; 35 kg/m2

         10. Use of investigational drugs or devices within 30 days prior to enrollment into the
             study.

         11. Life expectancy of less than 1 year due to non-cardiac pathology

         12. Any clinically significant abnormality identified at the time of screening that in the
             judgment of the Investigator or any sub-Investigator would preclude safe completion of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Siegel</last_name>
    <role>Study Director</role>
    <affiliation>Faraday Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Kórház</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ, Kardiológiai és Szívsebészeti Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Kórház</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. Prof. Leszka Kieca., III Oddz. Kardiologii</name>
      <address>
        <city>Katowice</city>
        <state>Silesia</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Specjalistyczny Szpital Zachodnii im. Jana Pawła II, Oddział Kardiologii Inwazyjnej</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Specjalistyczny Szpital Zachodnii im. Jana Pawła II, Oddział Kardiologii Inwazyjnej</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miedziowe Centrum Zdrowia</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Kardiologii Inwazyjnej; Centralny Szpital Kliniczny MSWiA w Warszawie</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLINIKA KARDIOLOGII, 4 Wojskowy Szpital Kliniczny</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Elektrokardiologii; Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital Cardiology Department</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <disposition_first_submitted>October 7, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 24, 2019</disposition_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03470441/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03470441/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

